T1	Participants 136 158	renal transplantation.
T2	Participants 234 282	(CMV) disease after renal transplantation (RTx).
T3	Participants 457 554	total of 38 patients was randomized to 3-month treatment with either oral ganciclovir (1 g t.i.d.
T4	Participants 556 605	n=14, GAN group) or oral valacyclovir (2 g q.i.d.
T5	Participants 607 623	n=12, VAL group)
